Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000492903 | SCV000582970 | likely pathogenic | not provided | 2016-06-20 | criteria provided, single submitter | clinical testing | The P390L missense variant in the CYBB gene has been reported previously, using alternate nomenclature, in association with X-linked Chronic Granulomatous Disease (CGD) (Roos et al., 1996), with limited evidence towards pathogenicity. It was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. P390L is a semi- conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position within the flavin adenine dinucleotide (FAD) binding domain that is conserved across species. While in silico analysis predicts this variant is probably damaging to the protein structure/function, and the FAD binding domain is essential in the function of the final translated superoxide protein (Kuhns et al., 2010), there is no published evidence regarding the functional effects of P390L. Yet missense variants in nearby residues (I385R, G389R/A/E/V) have been reported in the Human Gene Mutation Database in association with CGD (Stenson et al., 2014), supporting the functional importance of this region of the protein. Therefore, this variant is likely pathogenic; however, the possibility that it is benign cannot be excluded. |